Adeno-Associated Viral Vectors Based on Serotype 3b Use Components of the Fibroblast Growth Factor Receptor Signaling Complex for Efficient Transduction by Messina, Emily L. et al.
Research Articles
Adeno-Associated Viral Vectors Based on Serotype 3b Use
Components of the Fibroblast Growth Factor Receptor
Signaling Complex for Efficient Transduction
Emily L. Messina,1 Jeffrey Nienaber,1 Mani Daneshmand,1 Nestor Villamizar,1
Jude Samulski,2 Carmelo Milano,1 and Dawn E. Bowles3
Abstract
Adeno-associated virus type 3b (AAV3b) has been largely ignored by gene therapists because of the inability of
vectors based on this serotype to transduce target tissues efficiently. Here we describe a phenomenon unique to
AAV3b in that vectors based on this serotype mediate enhanced transduction in the presence of heparin. Among
the many biological functions attributed to heparin, its interaction with, and ability to regulate, several growth
factors (GFs) and growth factor receptors (GFRs) has been well characterized. Using GFR-overexpressing cell
lines, soluble GFs and heparins, as well as specific GFR inhibitors, we have demonstrated a requirement for
fibroblast growth factor receptor-2 (FGFR2) and FGF1 in the heparin-mediated augmentation of AAV3b vector
transduction. In contrast to AAV2, we establish that heparin can be used as an adjunct with AAV3b to further
increase transduction in a variety of cells and target tissues, additionally suggesting that AAV3b may be an
attractive viral vector for clinical use during procedures in which heparin is used. In summary, AAV3b exhibits
FGFR2-dependent, markedly enhanced transduction efficiency in the presence of heparin and FGFs, which could
make it a useful vector for gene therapy in a variety of human diseases.
Introduction
Adeno-associated viruses (AAVs) have been developedas vectors for gene therapy. Because AAV does not cause
disease, relatively little research has focused on defining the
infectious process of the 12 AAV serotypes (or hundreds of
AAV strains or laboratory-generated variants). As with any
biological intended for human use, a complete understanding
of the mechanisms of AAV vector transduction is essential for
ensuring safety and efficacy. Increased knowledge of the AAV
transduction process may lead to more successful gene ther-
apy applications.
AAV serotype 2 (AAV2) and the closely related AAV3 are
both derived from human sources (Hoggan et al., 1966).
AAV2 is the best characterized AAV at all levels of the in-
fectious process and infects a wide variety of cell types using
ubiquitously expressed heparan sulfate proteoglycan (HSPG)
as a primary attachment molecule (Summerford and Sa-
mulski, 1998). Initially deposited into the American Type
Culture Collection (ATCC, Manassas, VA) as AAV3 strain H
(VR-681; ATCC), two distinct AAV3 isolates (AAV3a and
AAV3b) differing by only six amino acids have been subse-
quently cloned (Muramatsu et al., 1996; Rutledge et al., 1998).
Both appear to bind to heparin and the infectivity of both is
inhibited by soluble heparin, albeit at much higher doses
than for AAV2 (Handa et al., 2000; Rabinowitz et al., 2004;
Lerch and Chapman, 2012). In comparison with vectors
based on other AAV serotypes, AAV3 vectors inefficiently
transduce most cell types with the exceptions of cochlear
inner hair cells (Chang et al., 2005) and human liver cancer
cells (Glushakova et al., 2009).
Similar to what has been discovered for unrelated viruses,
coreceptors are necessary for efficient AAV entry. Fibroblast
growth factor receptor-1 (FGFR1), hepatocyte growth factor
receptor (HGFR), avb5 integrin, and a5b1 integrin have all
been implicated as coreceptors for AAV2 (Qing et al., 1999;
Summerford et al., 1999; Kashiwakura et al., 2005; Asokan
et al., 2006). FGFR1 has been described as an AAV3h cor-
eceptor (Blackburn et al., 2006) and HGFR has been reported
as a coreceptor for AAV3 (Ling et al., 2010). It is noteworthy
that all aforementioned receptors have well-described inter-
actions with heparin or HSPG, which are in many cases
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critical for receptor functioning (Ornitz, 2000). Receptors,
both primary and coreceptors, for some serotypes have been
identified that do not appear to involve HSPG. Sialic acid
moieties are primary receptors for AAV1, AAV4, AAV5, and
AAV6 (Kaludov et al., 2001; Walters et al., 2001; Wu et al.,
2006); platelet-derived growth factor receptor (PDGFR) has
been recognized as a receptor for AAV5 (Di Pasquale et al.,
2003); and a laminin receptor has been reported used by
AAV2, AAV3, AAV8, and AAV9 (Akache et al., 2006).
In cell culture-based experiments, the glycosaminoglycan
heparin has been used as a substitute or competitive inhibi-
tor for HSPG. Infectivity of certain viruses including AAV2 is
inhibited in the presence of soluble heparin (Summerford
and Samulski, 1998; Dechecchi et al., 2000; Hilgard and
Stockert, 2000). Presumably, heparin attaches to heparin-
binding sites on the viral particle, directly blocking infection.
It is still unclear what influences heparin may exert on AAV2
transduction in vivo, and the effect may vary with the type or
form of heparin studied (Schuettrumpf et al., 2006). For ex-
ample, the presence of heparin serving a positive effect
in vivo has been seen after coinjection of AAV2 and heparin
in the brain (Nguyen et al., 2001; Mastakov et al., 2002).
Apparently, immediate binding to cell surface HSPG at the
site of injection was blocked by the presence of soluble
heparin, thereby allowing the vector to spread further from
the injection site.
When heparin is used experimentally in cell culture as a
competitive inhibitor to block infection, AAV3b is more re-
silient than AAV2 (Rabinowitz et al., 2004). This is believed
to occur because the AAV3b capsid interacts with less af-
finity to heparin than AAV2 (Rabinowitz et al., 2002; Lerch
and Chapman, 2012), a trait ascribed to its lack of high-
affinity heparin-binding sites that exist on the closely related
AAV2 capsid (Opie et al., 2003).
We decided to further explore this heparin-resistant phe-
notype of AAV3b for two reasons. First, surgical or percu-
taneous vector delivery methodology often necessitates
reversible and transient anticoagulation; AAV3b or similar
vectors containing the heparin resistance phenotype might
be advantageous for cardiovascular gene therapy. Second,
known coreceptors of AAV2 and AAV3b have well-
described interactions with either heparin or HSPG. It is
generally accepted that heparin plays an essential role in
FGFR signaling by direct association with both FGF and
FGFR on the cell surface (reviewed in Ornitz, 2000; Ornitz
and Itoh, 2001). Studying the AAV3b heparin-resistant phe-
notype might reveal more about AAV receptor interactions
and subsequent signaling events.
Here we report that AAV3b-based vectors possess the
unique and favorable property of significantly enhanced
transduction in the presence of soluble heparin. We have
undertaken studies to understand both why this occurs and
whether this effect can be translated from a cell culture ob-
servation to an in vivo model. Our results suggest that hep-
arin modulates an effect at AAV3b vector binding or entry
through the use of FGFR2 and fibroblast growth factors
(FGFs). Further inquiries indicate that signaling through
FGFRs confers a cellular environment more conducive to
infectivity of all tested AAV serotypes; it is not unique just to
AAV3b. These observations suggest that AAV vector trans-
duction in general may be optimal under conditions in which
FGFR signaling is enhanced, and that additional improve-
ments on AAV vector transduction can be made by directly
targeting cellular pathways influenced by FGFR signaling.
Materials and Methods
Cell lines
293, 911, A431, HEp-2, HeLa, and COS-7 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS) and penicillin
(100 U/ml)–streptomycin (100 lg/ml). 293G cells were
maintained in DMEM containing 10% FBS, 0.1 mM nones-
sential amino acids, G418 (600lg/ml), and penicillin (100 U/ml)–
streptomycin (100 lg/ml). CHO K1, CHO pgsD, PC3, and
A549 cells were maintained in Ham’s F-12 containing
10% FBS. SK-N-AS and SK-N-FI cells were maintained in
DMEM containing 10% FBS and 0.1 mM nonessential amino
acids. LNCaP cells were grown in RPMI 1640 medium con-
taining 2 mM l-glutamine, NaHCO3 (2 g/liter), 10% FBS,
10 mM HEPES, 1 mM sodium pyruvate, glucose (4.5 g/liter),
and penicillin (100 U/ml)–streptomycin (100 lg/ml). DU145
cells were maintained in DMEM, 10% FBS, 1 mM nonessen-
tial amino acids, 1 mM sodium pyruvate, and penicillin
(100 U/ml)–streptomycin (100 lg/ml). SUM-52 and SUM-44
cells (generously donated by S. Ethier, University of Michi-
gan Comprehensive Cancer Center, Ann Arbor, MI) were
grown according to their instructions. H16N2 pNG cells
were plated in Ham’s F-12 containing 2% FBS, insulin
(5 lg/ml), hydrocortisone (1 lg/ml), epidermal growth fac-
tor (EGF, 10 ng/ml), and G418 (100 lg/ml), and maintained
in the same without serum. H16N2 C1 and C3 cells were
split in Ham’s F-12 containing 2% FBS, insulin (5 lg/ml),
hydrocortisone (1 lg/ml), and G418 (100 lg/ml), and main-
tained in the same without serum. H16N2 cells and variants
were also provided by S. Ethier.
PCR
RNA was isolated from cell and vein samples, using an
RNeasy midi kit (Qiagen, Valencia, CA) as per the manu-
facturer’s instructions. cDNA was generated with a Tran-
scriptor first-strand cDNA synthesis kit (Roche, Basel,
Switzerland) according to the manufacturer’s instructions.
PCR was performed with a Platinum Taq DNA polymerase
kit (Invitrogen, Carlsbad, CA). PCRs were performed in a
PTC-200 thermo cycler (MJ Research, Waltham, MA). Primer
sequences and conditions for the FGFRs and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) PCR amplifications
were published by Tartaglia and colleagues (2001).
AAV production
All recombinant AAV vectors were produced via the
standard triple transfection method (reviewed in Grieger
et al., 2006), using the XX6-80 adenoviral helper plasmid with
a packaging plasmid (either pxr1-3 or the SASTG modified
plasmid) and an ITR plasmid carrying the luciferase trans-
gene. The plasmids were transfected into 293 cells with
polyethylenimine (Polysciences, Warrington, PA) and har-
vested 72 hr later. Cell suspensions were subjected to five
freeze–thaw cycles, followed by two CsCl gradients. The
isolated virus was then desalted on Econo-Pac 10DG col-
umns (Bio-Rad, Hercules, CA) and eluted in sterile
phosphate-buffered saline (PBS). Virus was quantified by
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nonradioactive dot blot, using a protocol described by
Grieger and colleagues (2006). Viruses that were to be di-
rectly compared were evaluated on the same blot.
Luminometer assays
Luminometry was performed with a Veritas luminometer
from Turner Biosystems (Sunnyvale, CA). Cells were plated at
10,000 cells per well in BD Falcon tissue culture-treated, 96-
well, black with clear bottom plates (Becton Dickinson,
Franklin Lakes, NJ). The cells were infected 24 hr later in
medium containing 2% FBS, unless otherwise stated. Other
growth factors, inhibitors, and glycosaminoglycans were not
used except where specifically stated. Cells were incubated
with virus (1000 particles/cell unless otherwise stated in the
text or figure legends) for 24 hr at 37C and subsequently
lysed with passive lysis buffer (Promega, Madison, WI) for
10 min. Within the luminometer, wells were injected with
100 ll of luciferase assay reagent (Promega) and, after a delay
of 2 sec, a measurement was taken for 10 sec. Each figure
shows results of experiments repeated at least twice with each
data point in triplicate or quadruplicate.
Glycosaminoglycan, FGF, and FGFR
inhibitor experiments
Twenty-four hours after plating, cells were pretreated with
100 ll of respective medium containing 2% FBS, unless oth-
erwise stated, and either no glycosaminoglycan (GAG), or a
dilution of GAG ranging from 1000 to 0.32 lg/ml (specific
range stated in figure legend). AAV vector was mixed with
medium containing no GAG or a dilution of the same GAG.
Pretreatment medium was then removed and replaced with
the same respective medium containing virus (1000 viral
genome-containing particles [VG]/cell unless otherwise stat-
ed) in a total volume of 100 ll. Cells were maintained at 37C
before and after infection, and during pretreatment. GAGs
used included chondroitin sulfate A, chondroitin sulfate C,
and heparin and were purchased from Sigma-Aldrich (St.
Louis, MO). Chondroitin sulfate B was purchased from US
Biological (Swampscott, MA). Heparin disaccharide and tet-
rasaccharide were purchased from Neoparin (Alameda, CA).
In experiments with growth factors, cells were infected in
serum-free medium containing FGF7 (KGF, 25 ng/ml) or
FGF1 (aFGF, 50 ng/ml). Growth factor was included in
growth media after plating, pretreatment and infection media.
FGF7 was obtained from Biovision (Mountain View, CA) and
FGF1 was obtained from Sigma-Aldrich. The FGFR inhibitor
PD173074 (Calbiochem, San Diego, CA) was resuspended in
dimethyl sulfoxide (DMSO). When PD173074 was used, a
DMSO-only control was also included. The inhibitor was used
in the pretreatment of cells and during infection at a concen-
tration of 8 · 10–3 lmol/ml. In the inhibitor experiment, a titer
of 10,000 VG/cell was used for AAV1.
FGF pull-down assays
AAV1, AAV2, or SASTG luciferase vector (3.8 · 1011 VG)
was mixed with 30 ng of FGF1 and 100 lg of heparin in a
total volume of 1 ml of cold PBS. Two micrograms of FGF1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was
mixed with 50 ll of A/G agarose slurry (Santa Cruz Bio-
technology) in a 1-ml volume of PBS. Mixtures were rocked
for 3 hr before the agarose mixture was spun down at
7000 rpm and the beads were washed twice in cold PBS.
Virus mixture was then added to the beads and the mixture
was rocked for an additional 2 hr. Mixtures were spun down
at 7000 rpm, supernatant was removed, and the beads were
washed in cold PBS. All of the above-described steps were
performed at 4C. At room temperature, beads were re-
suspended in 2· Laemmli buffer with 50 mM dithiothreitol
(DTT) and heated to 85C for 20 min. Twenty-five microliters
of the supernatant was run on a 10–20% Tris-glycine gel
(Invitrogen). After transfer and blocking, blots were probed
with anti-AAV B1 antibody (American Research Products,
Waltham, MA) at a 1:333 dilution.
Mouse leg injections in vivo imaging
Animals were maintained and treated in accordance with
the Institutional Animal Care and Use Committee (IACUC) at
Duke University (Chapel Hill, NC). All care and procedures
were in accordance with the Guide for the Care and Use of La-
boratory Animals (DHHS Publication No. [NIH] 85-23), and all
procedures received prior approval by Duke University In-
stitutional Animal Care and Usage Committees. Mice were
anesthetized and sedation was maintained with isoflurane.
Virus (1 · 1010 genome-containing viral particles) was pre-
mixed with heparin in PBS so that the final concentration of
heparin was 1.95, 31.2, or 260 lg/ml. The animal’s right gas-
trocnemius was injected with the mixture of heparin and vi-
rus, while the left was injected only with virus in an equal
injection volume. To image expression, mice were anesthe-
tized and sedation was maintained with isoflurane. One
hundred microliters of luciferin was delivered via intraperi-
toneal injection. The animals were imaged 10 min after injec-
tion, using the Xenogen IVIS imaging system (Caliper Life
Sciences, Hopkinton, MA) and luminescence was measured.
Vein experiments
After the Duke University Medical Center Institutional
Review Board provided exempted status, discarded saphe-
nous vein segments were obtained from patients undergoing
coronary artery bypass grafting. Vector delivery was
achieved by bathing pieces of the vein segments in vec-
tor and applying nondistending pressure to the entire
suspension.
Assessment of green fluorescent protein expression
in infected cells by flow cytometry analysis
911 cells were infected with SASTG-GFP (green fluores-
cent protein) virus as described previously. Three days
postinfection, cells were washed in PBS and fixed with 1%
paraformaldehyde. Cells were assessed with a FACSAria
flow cytometer (BD Biosciences, San Jose, CA) and FlowJo
software (Tree Star, Ashland, OR).
Cardiomyocyte isolation
All procedures for tissue procurement were performed in
compliance with institutional guidelines for an approved
IACUC protocol at Duke University Medical Center. Briefly,
porcine hearts were arrested with cold cardioplegia. The
myocardium was perfused by selective arterial cannulation
of the left anterior descending artery (LAD) or left circumflex
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arteries on a Langendorff apparatus. A modified Krebs
(Sigma-Aldrich) solution (25 mM NaHCO3, 10 mM taurine;
pH 7.4) was oxygenated and circulated at 37C for 10 min at
30 ml/min. The oxygenated collagenase solution (Krebs
[Sigma-Aldrich], type II collagenase [120 units/ml; Wor-
thington, Lakewood, NJ], 25 mM NaHCO3, 20 mM taurine,
20 mM 2,3-butanedione 2-monoxime [BDM], 0.05 mM CaCl2;
pH 7.4) was then circulated at 37C for 20 min. The heart was
then perfused with oxygenated rinse solution (Krebs [Sigma-
Aldrich], 25 mM NaHCO3, 10 mM taurine, 20 mM 2,3-BDM,
0.1 mM CaCl2, 10 ml/liter penicillin [100 U/ml]–streptomy-
cin [100 lg/ml]; pH 7.4) at 37C for 10 min. The heart was
then split at mid-myocardium and the myocytes were gently
scraped and rinsed into a Petri dish, using the rinse solution.
Cells were filtered and allowed to settle for 15 min. Part of
the supernatant was removed, the remaining volume was
diluted 1:1 with sterile low-calcium medium (Joklik’s MEM
with glutamine, 0.1 mM CaCl2, 1% bovine serum albumin
[BSA], 15 mM HEPES, 10 ml/liter penicillin [100 U/ml]–
streptomycin [100 lg/ml]; pH 7.4), and the cells were re-
suspended and allowed to settle for 15 min. Cells were then
subjected to calcium tolerance by increasing the CaCl2 con-
centration by 0.1 mM every 5 min to 0.5 mM. Cells were
plated on Matrigel (BD Biosciences) and incubated at 37C in
culture medium ( Joklik’s MEM with glutamine, 0.5 mM
CaCl2, 1% BSA, 5% FBS, 15 mM HEPES, 10 ml/liter penicillin
[100 U/ml]–streptomycin [100 lg/ml]; pH 7.4).
Results
Soluble heparin augments the ability of AAV3b-based
vectors to transduce tissue culture cells. Both AAV3a and
AAV3b have been reported to be inherently more resistant to
inhibition by heparin than AAV2 (Handa et al., 2000; Rabino-
witz et al., 2004). The heparin inhibition profiles of several
AAVs (AAV1, AAV2, and AAV3b) were further compared in a
dose–response experiment using 911 cells (Fig. 1A). As ex-
pected, AAV2 transduction was inhibited by heparin in a dose-
dependent manner, exhibiting 50% reduction at 15.6 lg/ml
and complete inhibition at higher doses (Summerford and
Samulski, 1998). In contrast, AAV1 was virtually unaffected by
heparin. Unexpectedly, as low a concentration as 1.95 lg/ml
of heparin boosted AAV3b transduction by approximately 22-
fold. This level of enhancement was maintained and increased
even further as the heparin concentration was raised over a 2-
fold range until a concentration of 250 lg/ml heparin was
reached, which diminished the enhancement to 8.7-fold over
baseline. Higher concentrations of heparin eventually in-
hibited AAV3b transduction. This clearly demonstrates a
significant and dramatic increase in transduction of the
AAV3b vector by heparin. We have extended our studies to
examine AAV6 and AAV9 (data not shown); the cell culture
transduction patterns of both are not enhanced by heparin.
Soluble heparin augments the ability of SASTG-based
vectors to transduce tissue culture cells. We have shown
that replacing critical amino acids in the AAV2 and AAV3b
capsid with the corresponding amino acids from AAV1
confers enhanced skeletal and cardiac muscle transduction
(Bowles et al., 2012; Piacentino et al., 2012). In the next set of
experiments we evaluated the influence of heparin on the
more efficient version of the AAV3b capsid, termed SASTG
(Piacentino et al., 2012). The response of AAV3b to heparin
was conserved in SASTG as judged by transduction experi-
ments performed in 911 cells with four independently gen-
erated preparations of SASTG-luc vector in the presence of
increasing amounts of heparin (Fig. 1B). Because SASTG
transduced target cells significantly more efficiently than
wild-type AAV3b, we chose to use the SASTG variant in the
remainder of the experiments in this study.
Regarding heparin-mediated augmentation of SASTG,
this phenomenon was observed whether luminometry was
performed at either 17 or 24 hr postinfection (Fig. 1B) or 48 hr
postinfection (Supplementary Fig. S1A; supplementary data
are available online at www.liebertpub.com/hum). A similar
boost was observed when SASTG transduction was assessed
in the setting of either porcine heparin (from two sepa-
rate preparations) or with bovine heparin (Supplementary
Fig. S1B and C).
To determine whether the observed heparin-mediated
enhancement was due to an increase in the number of in-
fected cells, or due to alterations in postentry events that
increase the level of transgene expression, 911 cells were
infected with SASTG-GFP vector in the absence or the
presence of two low doses (1.95 and 3.9 lg/ml) of heparin
(Fig. 1C). Flow cytometric analysis revealed both an increase
in the percentage of GFP-expressing cells as well as an in-
crease in the percentage of brighter cells at both doses of
heparin. These results suggest that heparin is influencing the
transduction process of SASTG at the level of vector binding
and entry, and possibly influencing postentry events.
The heparin-mediated augmentation correlates with
FGFR2 expression. Because results from the flow cytome-
try study indicated an involvement of vector binding and
entry and because an AAV coreceptor (FGFR1) was known to
interact with heparin, a panel of cell lines (Table 1) was ex-
amined for mRNA expression of the five FGFR family mem-
bers. From this we gleaned a positive correlation between the
presence of FGFR2 and heparin-mediated augmentation of
SASTG transduction. Transduction by SASTG requires the
presence of the FGFR2 receptor, as two different FGFR2-
specific small hairpin RNAs (shRNAs) decreased the ability of
SASTG to transduce 911 cells by 11-fold (shRNA 25) or 45-fold
(shRNA 24) (Fig. 2A). Treatment of cells with an FGFR2-
specific antibody before and during infection with the SASTG
vector blunted, but did not completely eliminate, the heparin-
mediated transduction boost (Fig. 2B). The requirement for
FGFR2 was further confirmed when the effects of heparin on
SASTG transduction were examined in H16N2 pNG cells,
which do not express the FGFR2 receptor, and in two deriv-
ative cell lines (C1 and C3) expressing an FGF1-sensitive form
of FGFR2 (C1 cells) or expressing a constitutively active
FGFR2 (C3 cells) (Moffa et al., 2004; Moffa and Ethier, 2007)
(Table 1, and Fig. 2C and D). SASTG transduced all cell lines
and the presence of the FGF1-sensitive form of FGFR2 did not
confer any enhancement over the pNG cells, in the absence of
heparin. However, the presence of the constitutively active
form of FGFR2 translated to a 4-fold increase in expression
over C1 cells for both SASTG and AAV2. In the presence of
heparin and FGF1, no enhancement in SASTG expression was
observed in either the pNG or C3 cells (Supplementary Fig.
S2). However, a significant enhancement in SASTG
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transduction was seen in C1 cells with the presence of both
FGF1 (50 ng/ml) and low levels of heparin (Fig. 2D).
Studies that compared the heparin effect in the SUM-52 PE
breast cancer cell line, which overexpresses nine splice vari-
ants of FGFR2, with SUM-44 PE cells, which do not over-
express FGFR2 (Tannheimer et al., 2000; Moffa et al., 2004;
Moffa and Ethier, 2007) (Table 1), confirmed the requirement
for FGFR2. Studies in prostate cancer cell lines LNCaP and
DU145, which exclusively express the IIIb and IIIc isoforms
of the FGFR2 receptor, respectively, suggest that the heparin-
mediated enhancement is due to the presence of FGFR2IIIb
(Fig. 2E). Non-FGFR2-expressing prostate cancer cells (PC3)
further reinforced the trend, exhibiting no heparin-mediated
enhancement of transduction (Fig. 2E). To examine the effect
of FGFR2 phosphorylation, we used an FGFR family inhib-
itor, PD173074, which targets the tyrosine kinase domain of
FGFR. A reduction of expression was observed with AAV1,
AAV2, and SASTG vectors in response to the addition of this
inhibitor (Fig. 2F). Together, these data suggest that activa-
tion and signaling from the FGFR2 receptor allow for more
efficient infectivity of AAV vectors in general.
Growth factors are necessary for the heparin effect. The
interactions of heparin with many growth factors (GFs) in-
cluding the ligands for FGFR2, the fibroblast growth factors
(FGFs), have been well characterized (Ornitz et al., 1996; Ornitz,
2000; Ornitz and Itoh, 2001; Zhang et al., 2006). Therefore, we
decided to examine the role that GFs may play in the heparin-
mediated augmentation of SASTG by first altering the source of
these GFs, the fetal bovine serum, and second, by blocking GFs
from interacting with their receptors and heparin. 911 cells
were grown in various concentrations of sera (0, 2, or 10%).
SASTG infections were then performed in medium at each of
FIG. 1. AAV1, AAV2, and AAV3b exhibit different trans-
duction profiles in 911 cells in the presence of increasing
amounts of soluble heparin. (A) Direct comparison of lucif-
erase expression between serotypes AAV1, AAV2, and
AAV3b in response to increasing concentrations of soluble
heparin. 911 cells were transduced with 10,000 particles per
cell of AAV1 or AAV3 and only 1000 particles per cell of
AAV2, all bearing the luciferase transgene. All transduction
experiments described were performed in the absence of an
adenoviral helper to eliminate compounding effects of a
second virus. The use of 10 times more AAV1 and AAV3 in
this experiment compared with AAV2 was done to obtain
reliable signals and is consistent with work performed pre-
viously. The vectors were applied to 911 cells in a 96-well
format. Infections were performed in the presence of in-
creasing amounts of heparin ranging from 0 to 1000 lg/ml in
2-fold serial dilutions. Light emitted from the infections was
assayed by luminometer the next day. These experiments in
911 cells were repeated a total of three times and data similar
to that shown in Fig. 1 were observed. Data represent
means – SD. (B) Response of AAV3b daughter vector,
SASTG, to soluble heparin. Four independently generated
preparations of the SASTG-luciferase vector gave similar
results in the presence of increasing amounts of heparin in
911 cells. SASTG vectors (1000 particles/cell) were applied to
911 cells (10,000 per well) in a 96-well format. Infections were
performed in the presence of increasing amounts of heparin
ranging from 0 to 1000 lg/ml in 2-fold serial dilutions. Light
emitted from the infections was assayed by luminometer the
next day. Data represent means – SD. (C) FACS assay dem-
onstrating the alteration of SASTG GFP expression in 911
cells with low concentrations of heparin. Infections were
performed in the presence of heparin (1.95 or 3.9 lg/ml).
GFP-positive cells were counted 5 days postinfection via
flow cytometry. Similar results were observed in three in-
dependent experiments. Data are presented as percent GFP-
positive cells and represent means – SD.
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the serum concentrations (Fig. 3A). Interestingly, in the absence
of heparin, SASTG transduction was highest at 0 and 2% se-
rum, whereas transduction in 10% serum was severely limited.
In the presence of heparin, an enhancement was observed in
both 2 and 10% serum, but significantly, not in 0% serum.
However, the enhancement effect in 0% serum was recapitu-
lated by the addition of FGF1. When infection was performed
in 2% serum with the addition of suramin (Fig. 3B), a molecule
that binds and inhibits the activity of many of the heparin-
binding growth factors (Moscatelli and Quarto, 1989; Ganesh
et al., 2005), the heparin enhancement was abrogated, reinfor-
cing the need for the presence of growth factors to achieve the
heparin augmentation effect.
To examine whether the SASTG vector physically inter-
acted with a growth factor or whether the heparin served to
cross-link the vector to the growth factor, in vitro pull-down
experiments were performed (Fig. 3C). Control immuno-
precipitation using anti-FGF1 antibodies performed on
SASTG vector incubated with either FGF1 or heparin, alone,
did not result in substantial vector pull-down (data not
shown). In contrast, of the three vectors examined (AAV3b
[SASTG] and AAV2 and AAV1) (Fig. 3C, lanes 1 to 3, re-
spectively) only the AAV3b-based capsids (lane 1) incubated
with FGF1 and heparin were pulled down by anti-FGF1
antibody, demonstrating the specificity of this phenomenon
to AAV3b and suggesting that the heparin cross-links the
AAV3b vector to the growth factor.
The type and size of the glycosaminoglycan (GAG) are
important for the heparin-mediated effect. To further char-
acterize the heparin-mediated augmentation of SASTG
transduction, the ability of heparins of various sizes and
related GAGs to mediate this process was examined (Fig. 4
and Supplementary Fig. S3). In all previously described
studies (Figs. 1–3), a heterogeneous heparin solution com-
posed of decasaccharides, undecasaccharides, and dodeca-
saccharides was used. When smaller, homogeneous heparins
such as a disaccharide (Fig. 4A), a tetrasaccharide (Fig. 4B),
or a hexasaccharide (Fig. 4C) were used, enhancement of
expression was observed at comparably higher doses. When
a low molecular mass (3-kDa) heparin with a calculated size
of an octasaccharide was used, low doses of this were suf-
ficient for heparin-mediated augmentation of transduction
(Fig. 4D). Of the other heparin-related molecules tested,
chondroitin sulfate A did not affect SASTG whereas chon-
droitin sulfate B and heparan sulfate elicited a small to
moderate enhancement (Supplementary Fig. S3). This cor-
responds to studies demonstrating that longer oligosaccha-
ride lengths, or more highly sulfated GAGs, are required to
efficiently activate FGFR2 (Mohammadi et al., 2005).
SASTG transduction in primary cells and tissues, and
in vivo can be enhanced by coadministration of hepa-
rin. Porcine cardiac myocytes and human saphenous vein
grafts were transduced in the setting of increasing heparin
concentrations (Fig. 5A and B). In each of these instances,
low doses of heparin served to augment SASTG transduc-
tion, mimicking what was observed in the studies using
immortalized cell lines.
To assess the SASTG response to heparin in vivo, BALB/c
mice were injected with SASTG and increasing amounts of
heparin in the right leg and with SASTG alone in the left (Fig.
5C–E). Mimicking the cell and tissue culture conditions, the
injections performed in the presence of the lowest amount of
heparin (Fig. 5C) exhibited an enhancement in transduction
compared with the contralateral leg. In contrast, intermediate
doses of heparin (31.2 lg/ml; Fig. 5D) coinjected with SASTG
had no influence on transduction efficiency. Higher doses of
heparin (260 lg/ml; Fig. 5E) minimized SASTG transduction.
These initial experiments demonstrate the potential for posi-




We report that AAV3b vectors have a unique property in
that their transduction ability is significantly enhanced in the
presence of low concentrations of heparin. Only one other
virus has been reported to be positively influenced by the
presence of heparin, a neuropathogenic PVC-211 murine
leukemia virus ( Jinno-Oue et al., 2001). In anticipation of
potential human applications, variables that alter the trans-
duction behavior of AAV vectors, even modestly, may be-
come critical. Here, we have carried out studies to
understand both how this heparin-mediated augmentation
occurs, and whether this effect can be translated from ob-
servations in established cell lines to primary cells and tis-
sues and to an in vivo mouse model.
Components of the heparin-mediated
enhancement effect
Our model for explaining the AAV3b heparin-mediated
enhancement is shown in Fig. 6. This model requires three
Table 1. Cell Lines and Tissues Used in Study
FGFR RNA
Cell line 1 2 3 4 5
Heparin
augmentation
293G + + + + + Yes
911 + + + + + Yes
Cos-7 + + – – + Yes
HF1 (293) + + + + + Yes
SK-N-AS + + – + + Yes
SK-N-FI + + – – + Yes
HeLa + – + + No
+
C2 C12 – – – – – No
CHOK1 – – – – – No
pqsD – – – – – No
A431 – – – – – No
A549 – – – – – No
HEp-2 + – + – + No
SUM-52 PE FGFR2 over
expressed
Yes
SUM-44 PE FGFR2 under
expressed
No
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FIG. 2. Examination of the importance of fibroblast growth factor receptor-2 (FGFR2) in SASTG infection. (A) SASTG
requires FGFR2 for infectivity. 911 cells transfected with either a control GFP plasmid or plasmids expressing shRNA (shRNA
24 or shRNA 25) specific for FGFR2 were infected 3 days posttransfection with SASTG-luc vector. Results are expressed as
fold decrease in SASTG infectivity relative to infections performed on untransfected cells. (B) Anti-FGFR2 antibody blunts
heparin-mediated SASTG transduction. Results are expressed as percent expression relative to infections performed in the
absence of heparin. (C) Infection of H16N2 cell lines (pNG, no FGFR2; C1, FGF1-sensitive FGFR2; C3, constitutively active
FGFR2) with SASTG-luc and AAV2-luc (1000 particles/cell) without heparin. Data represent means – SD. (D) Infection of
H16N2 C1 cells (10,000 per well) with SASTG-luc or AAV2-luc (1000 particles/cell) in the presence and absence of FGF
(50 ng/ml), over a range of heparin concentrations. Data represent means – SD. (E) Influence of heparin on SASTG trans-
duction of three prostate cancer cell lines expressing different isoforms of FGFR2. Respective cell lines (10,000 cells per well)
were infected with SASTG-luc (1000 particles/cell) in the presence of increasing amounts of heparin (ranging from 1 to 64 lg/
ml). Results are expressed as percent expression relative to infections performed in the absence of heparin. Data represent
means – SD. (F) Infection of 911 cells with an inhibitor of the tyrosine kinase domain of FGFR2, PD173074 (8 · 10–3 lmol/ml),
without heparin. The inhibitor was administered during pretreatment of the cells and during infection. A titer of 10,000 VG/
cell was used for AAV1 and 1000 VG/cell for AAV2 and SASTG. Data are normalized to infections performed without
inhibitor and are shown as means – SD.
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components: heparin, the presence of FGFR2, and an FGF,
either provided during infection or produced by the cell. To
the best of our knowledge, this scenario is unique to vectors
based on AAV3b. The first component, heparin (or cellular
HSPG), interacts with AAV3b. When one considers the role
of the GAG in the heparin-mediated augmentation, it is
important to note that an octasaccharide heparin is the
minimal length for FGF1 and FGFR2-induced dimerization
and subsequent activation (Mohammadi et al., 2005). In our
studies, a heparin molecule of a similar size exhibited
heparin-mediated augmentation at lower heparin doses.
Molecules smaller than eight sugars in length exhibited
heparin enhancement only at extremely high concentrations.
Increasing the size of the heparin to 10–12 saccharides con-
sistently achieved higher transduction than the 8-mer. Given
that longer heparin oligosaccharides can result in the for-
mation of multiple FGF–FGFR complexes on the same oli-
gosaccharide, these long GAGs exhibit more biological
activity (Faham et al., 1998; Harmer, 2006; Harmer et al.,
2006). We anticipate that increasing the size of the heparin
will further increase SASTG transduction efficiency.
The second component of the model is the presence of
FGFR2 on cells. Both AAV2 and AAV3b have been reported
to interact with GFRs and to possibly use these as a means of
cellular entry (Qing et al., 1999; Kashiwakura et al., 2005;
Blackburn et al., 2006). It seemed likely that these or similar
receptors were involved in the heparin-mediated augmen-
tation, given that GFRs and their ligands are known to in-
teract with heparin and/or HSPG. Using a panel of 18 cell
lines with established FGFR expression patterns, we per-
formed experiments to examine the interactions between
SASTG and heparin. A strong, positive correlation was
FIG. 3. Importance of growth factors
in the heparin-mediated augmentation
of SASTG. (A) Response of SASTG to
heparin under various serum concen-
trations. 911 cells (10,000 cells per well)
were infected with SASTG-luc
(1000 VG/cell) in the presence of vari-
ous serum concentrations (0, 2, 10, or
0% supplemented with FGF [50 ng/
ml]) across a range of heparin con-
centrations. Data represent means –
SD. (B) Alteration of the response of
SASTG to heparin with the addition of
suramin (100 lg/ml). Data represent
means – SD. (C) Coimmunoprecipita-
tion of SASTG with FGF1 in the pres-
ence of heparin and FGF1. AAV1,
AAV2, or SASTG-luciferase vector
(3.8 · 1011 VG) was mixed with 30 ng
of FGF1 and 100 lg of heparin and
subjected to immunoprecipitation with
2 lg of FGF1 antibody (Santa Cruz
Biotechnology). Twenty-five micro-
liters of the immunoprecipitation was
electrophoresed on a 10–20% Tris-
glycine gel (Invitrogen), transferred to
nitrocellulose, and probed with anti-
AAV B1 antibody (American Research
Products) at a 1:333 dilution.
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clearly seen between the presence of FGFR2 and a heparin-
mediated boost of expression. It is important to point out the
complexity of the FGFR family of receptors (reviewed in
Ornitz, 2000; Eswarakumar et al., 2005; Mohammadi et al.,
2005). There are five known members of this family (FGFR1–5)
as well as a multitude of isoforms generated by tissue-
specific splicing. Interestingly, RNA specific for FGFR5, a
newly discovered member of this family (Sleeman et al.,
2001), was detected in the majority of the cell lines examined
(Table 1), to the extent that we were never able to identify a
cell line that expressed only FGFR2 and not FGFR5. Our
attempts to knock down FGFR5 in these cells, using shRNA,
have been unsuccessful, presumably due to the high level of
expression of these transcripts in all cell types tested. How-
ever, to date, we have consistent data that the FGFR2 re-
ceptor is definitely involved, and we have suggestive data
that the involvement is specific for the FGFR2IIIb isoform
and not the FGFR2IIIc version (Fig. 2E). It is unclear whether
a combination of FGFR2 and FGFR5 might be needed for the
maximal effect, or even whether unique heterodimers of
these FGFRs could be conferring this effect.
The third component of the heparin-mediated effect is the
presence of growth factor. This was evidenced by the obser-
vation that the addition of growth factor to the medium
augmented SASTG transduction in the absence of heparin
(Fig. 3A) and by the establishment that SASTG incubated in
the presence of FGF1 and heparin can be pulled down by anti-
FGF1 antibodies. This observation was specific for SASTG and
was not observed with other vectors tested. It has been re-
ported that FGF1 blocks AAV2 from entry by competing for
FGFR1 (Qing et al., 1999). A simple explanation for the ob-
served enhancement is that heparin is binding to the GFs in
the medium, and thereby preventing them from interfering
with AAV3b viral entry. This explanation may play a role
under high-GF conditions (i.e., in the presence of 10% FBS;
Fig. 3A) but fails to explain the full phenomenon. Low to
moderate levels of GF (which may more closely reflect an
in vivo scenario) are essential, not detrimental, to the en-
hancement. Removing them from the infection either through
performing the infections under serum-free conditions, or by
using suramin (a drug that blocks the biological activity of
heparin-binding growth factors) (Moscatelli and Quarto, 1989;
Ganesh et al., 2005), abolishes the affect. Addition of the
growth factor back to the cells reconstitutes this effect. Thus
we propose that the addition of soluble heparin allows
AAV3b-based vectors to interact with the dimerized active
FGFR2:FGF complex, thereby enhancing virus transduction
through increased binding and entry and FGFR2 signaling.
Understanding AAV–receptor interactions
To add to the base knowledge of AAV receptor interac-
tions, we have determined that components of the FGFR
signaling complex are critical in the heparin-mediated
FIG. 4. Evaluation of heparins in their ability to enhance SASTG expression and inhibit AAV2. 911 cells (10,000 cells per
well) were infected with SASTG-luc or AAV2-luc (1000 VG/cell) in the presence of (A) a small heparin disaccharide, (B) a
tetrasaccharide, (C) a hexasaccharide, and (D) an octasaccharide over a range of heparin concentrations. Data represent
means – SD.
AAV3b VECTOR TRANSDUCTION BY FGFR SYSTEM 1039
augmentation of SASTG transduction. In cells that express
FGFR2, AAV3b and SASTG infect with less efficiency when
heparin is absent (Fig. 6A), but under optimal heparin con-
ditions that augment FGFR dimerization, SASTG infects more
efficiently (Fig. 6B). In addition, relatively little is known re-
garding subsequent signaling events arising from AAV vector
interactions with receptors. Whether the receptors internalize
with the vector or whether the binding of the virus influences
normal receptor signaling is unclear. Our results using an
FGFR inhibitor, as well as cell lines expressing different forms
of the FGFR2 receptor, reveal that signaling via FGFR is im-
portant for AAV infectivity in general. This is in direct con-
trast to the study by Qing and colleagues (1999). There they
report that FGFR inhibitors have no influence on AAV2
transgene expression. The disparity between our results and
theirs may be due to differences in the type of inhibitor used
in the two studies, although crystallographic studies show
that both SU5402 (one of the inhibitors used in the Qing et al.
studies) and PD173074 (used in our studies) bind in the ATP-
binding cleft of the FGFR1 tyrosine kinase domain between
the two lobes of the kinase (Mohammadi et al., 1997). Alter-
natively, differences in cell lines or amounts of inhibitor used
may explain the differences in results.
Clinical situations in which SASTG plus
heparin would be beneficial
There are several clinical situations in which SASTG and
heparin might be useful. For example, most surgical proce-
dures require anticoagulation, usually with heparin, and
gene therapy performed in the context of such a surgery
would therefore potentially expose the viral vector to hepa-
rin. In addition, AAV vectors are being developed for
treatments of vein grafts in the prevention of vein graft
failure. One of the primary causes of vein graft failure is
vascular smooth muscle cell (VSMC) proliferation. Studies in
cell culture and animal models have shown that heparin is
capable of inhibiting vascular smooth muscle proliferation,
and human clinical trials have suggested that low molecular
weight forms of heparin can inhibit intimal hyperplasia as-
sociated with vein graft failure (Kiesz et al., 2001; Wilensky
et al., 2000). Perhaps an SASTG vector codelivered with
heparin may synergistically confer higher levels of gene ex-
pression and prevent initial onset of intimal hyperplasia.
A highly efficient viral vector such as SASTG, which uses
FGFR2, shows unique potential for targeted gene delivery to
breast and prostate tumors. FGFR2 was deemed highly as-
sociated with sporadic postmenopausal human breast cancer
(Easton et al., 2007; Hunter et al., 2007). In addition, in human
models of prostate cancer, changes in the expression patterns
of FGFR2 isoforms seem to play a role in the development of
prostate cancer. This isoform switch often correlates with
androgen insensitivity and a more aggressive prostate cancer
phenotype (Carstens et al., 1997). Potentially, by further un-
derstanding SASTG–FGFR2 interactions, the SASTG vector
could be exploited in vivo to precisely target cells expressing
specific isoforms of FGFR2.
In adults, the FGFRs and FGFs function in tissue repair and
wound healing. FGFRs and their FGF ligands are up-regulated
during many types of tissue injury. Further study is required to
determine whether SASTG may be a useful gene therapy vec-
tor in the context of injured or diseased tissue. Understanding
FIG. 5. SASTG-luciferase expression in response to heparin
in primary cell culture, tissue, and in vivo. (A) Primary por-
cine cardiomyocytes plated in 6-well dishes were infected
with SASTG-luc and increasing amounts of heparin. Two
days postinfection, cells were harvested, lysed, and subjected
to luminometry. Results are expressed as relative light units
(RLUs) normalized to milligrams of total protein. (B) Human
saphenous vein transduced with SASTG and heparin. (C–E)
Evaluation of in vivo skeletal muscle transduction of SASTG
plus heparin, using in vivo biophotonic imaging of hind leg
injections. Image showing SASTG expression with heparin
injected into the (animal’s) right leg and SASTG without
heparin in the (animal’s) left leg. Various doses of heparin
were used (low, 1.95 lg/ml; medium, 31.2 lg/ml; and high,
260lg/ml). Increasing wavelength reflects greater luminescence.
Color images available online at www.liebertpub.com/hum
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the exact relationship between SASTG and FGFR/cofactor/
heparin requirements will facilitate this process.
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